NanoViricides' NV-387 shows promise as broad antiviral amid deadly hantavirus cruise ship outbreak

NanoViricides highlights its antiviral drug NV-387 as a potential solution during a deadly hantavirus outbreak on a cruise ship. NV-387 has completed Phase I trials showing safety and effectiveness against multiple viruses, including those spreading via respiratory routes like the Andes hantavirus. The drug targets viral entry mechanisms common to over 90% of pathogenic viruses, offering an advantage over vaccines and antibody therapies. NanoViricides aims to position NV-387 as a rapid first-response treatment to control outbreaks early and protect close contacts prophylactically.